Journal of Gastroenterology

, Volume 31, Issue 6, pp 898–906

Cyclooxygenase, NSAIDs, and colorectal cancer

  • Raymond N. DuBois
  • Walter E. Smalley


Prevention of human diseases has become a major focus of biomedical investigators around the world. Our current screening and treatment regimens for colorectal cancer are not effective, as indicated by the fact that this disease is the second leading cause of death from cancer in the United States. Recently published reports indicate that continuous use of aspirin reduces the relative risk of colorectal cancer by about 50%. Other work demonstrates that NSAIDs cause regression of adenomas in patients with familial adenomatous polyposis and prevent the development of colon tumors in carcinogen-treated animals. This review is a summary of the literature and includes an analysis of recent reports indicating the potential molecular basis for the chemoprotective effects of NSAIDs.

Key words

colon cancer NSAIDs cyclooxygenase prevention 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Miller AB, Howe GR, Jain M. Food items and food groups at risk factors in a case-control study of diet and colon cancer. Int J Cancer 1983;32:155–162.PubMedGoogle Scholar
  2. 2.
    Wynder EL, Kajitani T, Ishikawa S, Dodo H, Takano A. Environmental factors of cancer of colon and rectum. II. Japanese epidemiological data. Cancer 1969;23:1210–1220.PubMedGoogle Scholar
  3. 3.
    Yokoyama C, Tanabe T, Cloning of human gene encoding prostaglandin endoperoxide synthase and primary structure of the enzyme. Biochem Biophys Res Commun 1989;165:888–894.CrossRefPubMedGoogle Scholar
  4. 4.
    Hla T, Neilson K. Human cyclooxygenase-2 cDNA. Proc Natl Acad Sci USA 1992;89:7384–7388.PubMedGoogle Scholar
  5. 5.
    Marnett L. Aspirin and the potential role of prostaglandins in colon cancer. Cancer Res 1992;52:5575–5589.PubMedGoogle Scholar
  6. 6.
    Smith WL, Marnett LJ. Prostaglandin endoperoxide synthase: Structure and catalysis Biochim Biophys Acta 1991;1083:1–17.PubMedGoogle Scholar
  7. 7.
    Vane J. Towards a better aspirin. Nature 1994;367:215–216.CrossRefPubMedGoogle Scholar
  8. 8.
    Williams CW, DuBois RN. Prostaglandin endoperoxide synthase: Why two isoforms. Am J Phys 1996;270:G393-G400.Google Scholar
  9. 9.
    Jones DA, Carlton DP, McIntyre TM, et al. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993;268:9049–9054.PubMedGoogle Scholar
  10. 10.
    DuBois RN, Tsujii M, Bishop P, et al. Cloning and characterization of a growth factor-inducible cyclooxygenase gene from rat intestinal epithelial cells. Am J Phys 1994;266:G822-G827.Google Scholar
  11. 11.
    Kujubu DA, Fletcher BS, Varnum BC, et al. TIS10, a phorbol ester tumor promoter-inducible mRNA from Swiss 3T3 cells, encodes a novel prostaglandin synthase/cyclooxygenase homologue. J Biol Chem 1991;266:12866–12872.PubMedGoogle Scholar
  12. 12.
    Shimokawa T, Smith WL. Prostaglandin endoperoxide synthase. The aspirin acetylation region. J Biol Chem 1992;267:12387–12392.PubMedGoogle Scholar
  13. 13.
    Capdevila JH, Morrow JD, Belosludtsev, YY, et al. The catalytic outcomes of the constitutive and the mitogen inducible isoforms of prostaglandin H2 synthase are markedly affected by, glutathione and glutathione peroxidase(s). Biochemistry 1995;34: 3325–3337.CrossRefPubMedGoogle Scholar
  14. 14.
    Meade EA, Smith WL, DeWitt DL. Differential inhibition of prostaglandin endoperoxide synthase (cyclooxygenase) isozymes by aspirin and other non-steroidal antiinflammatory drugs. J Biol Chem 1993;268:6610–6614.PubMedGoogle Scholar
  15. 15.
    Holtzman MJ, Turk J, Shornick LP. Identification of a pharmacologically distinct prostaglandin H synthase in cultured epithelial cells. J Biol Chem 1992;267:21438–21445.PubMedGoogle Scholar
  16. 16.
    Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990;61:759–767.CrossRefPubMedGoogle Scholar
  17. 17.
    Peipins LA, Sandler RS. Epidemiology of colorectal adenomas. Epidemiol Rev 1994;16:273–297.PubMedGoogle Scholar
  18. 18.
    Fearon ER. Molecular genetic studies of the adenoma-carcinoma sequence. Adv Int Med 1994;39:123–147.Google Scholar
  19. 19.
    Hamilton SR. The molecular genetics of colorectal neoplasia. Gastroenterology 1993;105:3–7.PubMedGoogle Scholar
  20. 20.
    Rustgi AK. Molecular genetics and colorectal cancer. Gastroenterology 1993;104:1223–1225.PubMedGoogle Scholar
  21. 21.
    Boland CR. The biology of colorectal cancer. Implications for pretreatment and follow-up management. Cancer 1993;71:4180–4186.PubMedGoogle Scholar
  22. 22.
    Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res 1995; 55:1811–1816.PubMedGoogle Scholar
  23. 23.
    Greenberg ER, Baron JA, Freeman DHJ, et al. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst 1993;85:912–916.PubMedGoogle Scholar
  24. 24.
    Hixson LJ, Alberts DS, Krutzsch M, et al. Antiproliferative effect of nonsteroidal antiinflammatory drugs against human colon cancer cells. Cancer Epidemiol Biomarkers Prev 1994; 3:433–438.PubMedGoogle Scholar
  25. 25.
    Landenheim J, Garcia G, Titzer D, et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology 1995;108:1083–1087.Google Scholar
  26. 26.
    Kudo T, Narisawa T, Abo S. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann 1980;71:260–264.PubMedGoogle Scholar
  27. 27.
    Pollard M, Luckert PH. Indomethacin treatment of rats with dimethylhydrazine-induced intestinal tumors. Cancer Treat Rep 1980;64:1323–1327.PubMedGoogle Scholar
  28. 28.
    Pollard M, Luckert PH. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981;214:558–559.PubMedGoogle Scholar
  29. 29.
    Narisawa T, Sato M, Sano M, Takahashi T. Inhibition of development of methylnitrosourea-induced rat colonic tumors by peroral administration of indomethacin. Gann 1982;73:377–381.PubMedGoogle Scholar
  30. 30.
    Narisawa T, Satoh M, Sano M, Takahashi T. Inhibition of initiation and promotion by N-methylnitrosourea-induced colon carcinogenesis in rats by non-steroid anti-inflammatory agent indomethacin. Carcinogenesis 1983;4:1225–1227.PubMedGoogle Scholar
  31. 31.
    Pollard M, Luckert PH, Schmidt MA. The suppressive effect of piroxicam on autochthonous intestinal tumors in the rat. Cancer Lett 1983;21:57–61.CrossRefPubMedGoogle Scholar
  32. 32.
    Narisawa T, Hermanek P, Habs M, Schmahl D. Reduction of carcinogenicity of N-nitrosomethylurea by indomethacin and failure of resuming effect of prostaglandin E2 (PGE2) against indomethacin. J Cancer Res Clin Oncol 1984;108:239–242.CrossRefPubMedGoogle Scholar
  33. 33.
    Metzger U, Meier J, Uhlschmid G, Weihe H. Influence of various prostaglandin synthesis inhibitors on DMH-induced rat colon cancer. Dis Colon Rectum 1984;27:366–369.PubMedGoogle Scholar
  34. 34.
    Pollard M, Luckert PH. Prolonged antitumor effect of indomethacin on autochthonous intestinal tumors in rats. J Natl Cancer Inst 1983;70:1103–1105.PubMedGoogle Scholar
  35. 35.
    Pollard M, Luckert PH. Effect of piroxicam on primary intestinal tumors induced in rats by N-methylnitrosourea. Cancer Lett 1984;25:117–121.PubMedGoogle Scholar
  36. 36.
    Nigro ND, Bull AW, Boyd ME. Inhibition of intestinal carcinogenesis in rats: Effect of difluoromethylornithine with piroxicam or fish oil. J Natl Cancer Inst 1986;77:1309–1313.PubMedGoogle Scholar
  37. 37.
    Reddy BS, Maruyama H, Kelloff G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res 1987;47:5340–5346.PubMedGoogle Scholar
  38. 38.
    Ross DS, Bitzer D, Roy T, Murphy JE. Piroxicam inhibits the growth of an adenocarcinoma isograft in Fischer rats. J Surg Res 1988;45:249–253.CrossRefPubMedGoogle Scholar
  39. 39.
    Pollard M, Luckert PH. In vivo model systems for assessing an anti-cancer drug: Responses of autochthonous and transplanted prostate tumors to cyclophosphamide. Anticancer Res 1990; 10:33–36.PubMedGoogle Scholar
  40. 40.
    Rao CV, Tokumo K, Rigotty J, et al. Chemoprevention of colon carcinogenesis by dietary administration of piroxicam, alpha-difluoromethylornithine, 16 alpha-fluoro-5-androsten-17-one, and ellagic acid individually and in combination. Cancer Res 1991;51:4528–4534.PubMedGoogle Scholar
  41. 41.
    Jacoby RF, Marshall DJ, Newton MA, et al. Chemoprevention of spontaneous intestinal adenomas in the ApcMin mouse model by the nonsteroidal anti-inflammatory drug piroxicam. Cancer Res 1996;56:710–714.PubMedGoogle Scholar
  42. 42.
    Moorghen M, Ince P, Finney KJ, et al. A protective effect of sulindac against chemically induced primary colonic tumours in mice. J Pathol 1988;156:341–347.CrossRefPubMedGoogle Scholar
  43. 43.
    Moorghen M, Ince P, Finney KJ, et al. The effect of sulindac on colonic tumour formation in dimethylhydrazine-treated mice. Acta Histochem (Suppl) 1990;39:195–199.Google Scholar
  44. 44.
    Skinner SA, Penney AG, O'Brien PE, Sulindac inhibits the rate of growth and appearance of colon tumors in the rat. Arch Surg 1991;126:1094–1096.PubMedGoogle Scholar
  45. 45.
    Reddy BS, Rao CV, Rivenson A, Kelloff G. Inhibitory effect of aspirin on azoxymethane-induced colon carcinogenesis in F344 rats. Carcinogenesis 1993;14:1493–1497.PubMedGoogle Scholar
  46. 46.
    Reddly BS, Nayini J, Tokumo K, et al. Chemoprevention of colon carcinogenesis by concurrent administration of piroxicam, a nonsteroidal antiinflammatory drug withD,L-alpha-difluoromethylornithine, an ornithine decarboxylase inhibitor, in diet. Cancer Res 1990;50:2562–2568.Google Scholar
  47. 47.
    Reddy BS, Tokumo K, Kulkarni N, et al. Inhibition of colon carcinogenesis by prostaglandin synthesis inhibitors and related compounds. Carcinogenesis 1992;13:1019–1023.PubMedGoogle Scholar
  48. 48.
    Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995;55:1464–1472.PubMedGoogle Scholar
  49. 49.
    DuBois RN, Radhika A, Reddy BS, Entingh AJ. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterology 1996;110:1259–1262.CrossRefPubMedGoogle Scholar
  50. 50.
    Moser AR, Pitot HC, Dove WF. A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. Science 1990;247:322–325.PubMedGoogle Scholar
  51. 51.
    Su LK, Kinzler KW, Vogelstein B, et al. Multiple intestinal neoplasia caused by a mutation in the murine homolog of the APC gene. Science 1992;256:668–670.PubMedGoogle Scholar
  52. 52.
    Oshima M, Oshima H, Kitagawa K, et al. Loss ofApc heterozygosity and abnormal tissue building in nascent intestinal polyps in mice carrying a truncatedApc gene. Proc Natl Acad Sci USA 1995;92:4482–4486.PubMedGoogle Scholar
  53. 53.
    MacPhee M, Chepenik K, Liddell R, et al. The secretory phospholipase A2 gene is a candidate for the Mom1 locus, a major modifier of Apcmin-induced intestinal neoplasia. Cell 1995;81:957–966.CrossRefPubMedGoogle Scholar
  54. 54.
    Kinzler KW, Nilbert MC, Su LK, et al. Identification of FAP locus genes from chromosome 5q21. Science 1991;253:661–665.PubMedGoogle Scholar
  55. 55.
    Nishisho I, Nakamura Y, Miyoshi Y, et al. Mutations of chromosome 5q21 genes in FAP and colorectal cancer patients. Science 1991;253:665–669.PubMedGoogle Scholar
  56. 56.
    Su LK, Vogelstein B, Kinzler KW. Association of the APC tumor suppressor protein with catenins. Science 1993;262:1734–1737.PubMedGoogle Scholar
  57. 57.
    Powell SM, Zilz N, Beazer-Barclay Y, et al. APC mutations occur early during colorectal tumorigenesis. Nature 1992;359:235–237.CrossRefPubMedGoogle Scholar
  58. 58.
    Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983;24:83–87.PubMedGoogle Scholar
  59. 59.
    Waddell WR, Gastner GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989;157:175–178.CrossRefPubMedGoogle Scholar
  60. 60.
    Tonelli F, Valanzano R. Sulindac in familial adenomatous polyposis. Lancet 1993;342:1120–1120.CrossRefPubMedGoogle Scholar
  61. 61.
    Rigau J, Pique JM, Rubio E, et al. Effects of long-term sulindac therapy on colonic polyposis. Ann Intern Med 1991;115:952–954.PubMedGoogle Scholar
  62. 62.
    Winde G, Gumbinger HG, Osswald H, et al. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: Clinical results of a dose-finding study on rectal sulindac administration. Int J Colorectal Dis 1993;8:1317.CrossRefGoogle Scholar
  63. 63.
    Labayle D, Fischer D, Vielh P, et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991;101:635–639.PubMedGoogle Scholar
  64. 64.
    Giardiello FM, Hamilton SR, Krush AJ et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993;328:1313–1316.CrossRefPubMedGoogle Scholar
  65. 65.
    Nugent KP, Farmer KC, Spigelman AD, et al. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br J Surg 1993;80:1618–1619.PubMedGoogle Scholar
  66. 66.
    Giovannucci E, Rimm EB, Stampfer MJ, et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994;121:241–246.PubMedGoogle Scholar
  67. 67.
    Kune KA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: Case control results from the Melbourne colorectal cancer study. Cancer Res 1988;48: 4399–4404.PubMedGoogle Scholar
  68. 68.
    Rosenberg L, Palmer JR, Zauber AG, et al. A hypothesis: Nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst 1991;83:355–358.PubMedGoogle Scholar
  69. 69.
    Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer 1993;72:1171–1177.PubMedGoogle Scholar
  70. 70.
    Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Int Med 1994;154:394–399.Google Scholar
  71. 71.
    Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer 1994;74:1847–1854.PubMedGoogle Scholar
  72. 72.
    Paganini-Hill A, Chao A, Ross RK, Henderson BE. Aspirin use and chronic diseases: A cohort study of the elderly. BMJ 1989; 299:1247–1250.PubMedGoogle Scholar
  73. 73.
    Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology 1994;5:138–146.PubMedGoogle Scholar
  74. 74.
    Thun MJ, Namboodiri MM, Heath CWJ. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991;325:1593–1596.PubMedGoogle Scholar
  75. 75.
    Muscat JE, Wynder EL. Anti-inflammatory drugs and rheumatoid arthritis. J Natl Cancer Inst 1993;85:921–922.PubMedGoogle Scholar
  76. 76.
    Giovannucci E, Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995;333:609–614.CrossRefPubMedGoogle Scholar
  77. 77.
    Physician's Health Study Group Preliminary Report. Findings from the aspirin component of the ongoing Physician's Health Study. N Engl J Med 1995;318:262–264.Google Scholar
  78. 78.
    Physicians' Health Study Group Final Report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989;321:129–135.Google Scholar
  79. 79.
    Eberhart CE, Coffey RJ, Radhika A, et al. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994;107:1183–1188.PubMedGoogle Scholar
  80. 80.
    Kargman S, O'Neill G, Vickers P, et al. Expression of prostaglandin G/H synthase-1 and 2-protein in human colon cancer. Cancer Res 1995;55:2556–2559.PubMedGoogle Scholar
  81. 81.
    Sano H, Kawahito Y, Wilder RL, et al. Expression of cyclooxygenase-1 and-2 in human colorectal cancer. Cancer Res 1995;55:3785–3789.PubMedGoogle Scholar
  82. 82.
    Shiff SJ, Qiao L, Tsai LL, et al. Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells. J Clin Invest 1995;96:491–503.PubMedGoogle Scholar
  83. 83.
    Lu X, Xie W, Reed D, et al. Nonsteroidal antiinflammatory drugs cause apoptosis and induce cyclooxygenase in chicken embryo fibroblasts. Proc Natl Acad Sci USA 1995;92:7961–7965.PubMedGoogle Scholar
  84. 84.
    Piazza GA, Rahm AL, Krutzsch M, et al. Antineoplastic drugs sulindac sulfide and sulfone inhibit cell growth by inducing apoptosis. Cancer Res 1995;55:3110–3116.PubMedGoogle Scholar
  85. 85.
    Williams CW, Luongo C, Radhika A, et al. Elevated cyclooxygenase-2 levels inMin mouse adenomas. Gastroenterology 1996;111:1134–1140.CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag 1996

Authors and Affiliations

  • Raymond N. DuBois
    • 1
    • 2
  • Walter E. Smalley
    • 1
  1. 1.Department of Medicine, Veterans Affairs Medical CenterVanderbilt University Medical CenterNashvilleUSA
  2. 2.Department of Cell Biology, Veterans Affairs Medical CenterVanderbilt University Medical CenterNashvilleUSA

Personalised recommendations